The invention discloses a compound
medicine composite with a
breast cancer resistance function, application of the composite and
medicine based on the composite. The active content of the compound
medicine composite is composed of
doxorubicin and
piperlongumine with the
mole ratio of 1:5-1:15. According to an experiment, an MDA-MB-231
human breast cancer cell is used as a model, and through an MTTexperiment, by applying CompuSyn
software analysis, it is discovered that a good synergistic effect is achieved during compatibility of
doxorubicin and
piperlongumine with the
mole ratio of 1:10; through a
cell apoptosis experiment, it is discovered that the
apoptosis-promoting effect is obviously superior that that of a single medicine group when the two kinds of medicines cooperate for use; through a naked mouse
cancer-bearing medicine application experiment, it is discovered that growth of heterograft tumors of MDA-MB-231 cells in the naked mouse can be effectively inhibited through a medicine cooperation application group, and the effect of the medicine cooperation application group is obviously superior that that of the single medicine group. In this way, medicine cooperation application of
doxorubicin and
piperlongumine has the high function of inhibiting the
breast cancer through cooperation, and accordingly the composite has good clinical medicine application development prospects.